REVA Medical, Inc. and the New Jersey Center for Biomaterials
Collaborate to Develop the First Fully Bioreabsorbable Polymer
Drug Delivery Stent that is Visible by X-ray
SAN DIEGO, CA (September 15, 2003) -- REVA Medical, Inc. and the New Jersey Center for Biomaterials have joined forces to develop the first bioreabsorbable polymer drug-delivery stent that is visible by X-ray radiography/fluoroscopy. X-ray visibility is necessary for placement accuracy and continued monitoring of the device after implantation.
Bioreabsorbable stents have many inherent advantages over permanent metal devices currently used to treat narrowing of the arteries of the heart and other areas of the body. Metal drug-eluting stents are limited to a thin polymer matrix for drug delivery. A bioreabsorbable polymer stent can potentially deliver a greater drug payload over a longer period of time to limit the occurrence of localized restenosis, or re-narrowing, of vessels. This type of stent also presents a unique opportunity to locally deliver two or more drugs over multiple time scales to treat a variety of clinical conditions. Once the drug is delivered and vessel function is restored, the polymer will be completely resorbed, leaving no permanent implant behind.
The selected materials for the stent development program are a family of tyrosine-derived polycarbonates, versatile, degradable polymers with proven biocompatibility, developed by Dr. Joachim Kohn, Director of the New Jersey Center for Biomaterials. In his recent presentation at the September 11th Stent Technologies in Endoluminal Therapies Summit at the Cleveland Clinic, Dr. Kohn, who is also a Rutgers University Board of Governors Professor of Chemistry and Chemical Biology, explained that, "Tyrosine-derived polycarbonates combine sufficient mechanical properties for stent manufacture with a high degree of biocompatibility. X-ray visibility is achieved by the inclusion of iodine atoms to the polymer."
The polymer is combined with the REVA Medical slide-and-lock technology, a highly innovative stent design that allows deployment without significant deformation of the stent structure. This is a major advantage as polymers are not as resistant to deformation as metals. Commented Robert K. Schultz, PhD, President, REVA Medical; "The slide-and-lock technology allows REVA to create fully bioreabsorbable stents ¬ something traditional deformable stent designs simply can’t achieve. REVA’s stent design is a highly differentiated piece of intellectual property that presents a clear path to stent commercialization. We are aggressively pursing strategic partnerships to successfully bring this technology to market."
In-vivo studies have demonstrated that stents with the slide-and-lock design can be made of poly (DTE carbonate) and be successfully deployed in femoral and coronary porcine arteries using standard balloon deployment. According to Dr. James Anderson, MD, PhD, Case Western Reserve University, "Histological evaluation of poly (DTE carbonate) stents at 28 days in porcine arteries revealed a normal healing response with a normal foreign body reaction at the tissue/material interface and no acute and/or chronic inflammation." Additional work with poly (DTE carbonate) as an anti-restenosis drug-delivery vehicle demonstrates the significant potential of this polymer for vascular applications. Together these studies are of major significance as they illustrate the potential of these novel stent materials and designs in the treatment of vascular disease.
REVA Medical, Inc. (www.teamreva.com) was founded in 1998 with the mission to deliver novel solutions for the treatment of vascular disease. REVA holds multiple proprietary patents on product designs, which promise to revolutionize the cardiovascular industry. At present, REVA has two stent development programs under way, each which employ a patented and unique stent design. REVA’s sister-company, Happy Valley Medical, Inc. (www.happyvalleymedical.com) features a complementary development program involving Ceracor™, a proprietary and promising anti-restenotic agent.